TP53 and cancer: Although these mutations have not yet been identified in cancer, they have two important features: first, the precise mechanism of action—reduction of cooperativity leading to weakened DNA binding—is well characterized for these mutations; second, as suggested by structural data and confirmed in multiple experiments, these mutations do not affect p53 monomer structure.